Mucositis (Oral and Gastrointestinal)

  • Rajesh V. Lalla
  • Dorothy M. K. Keefe


Alimentary mucositis refers to inflammatory, erosive, and ulcerative lesions of any part of the gastrointestinal (GI) tract that occur secondary to cancer therapy. Thus, the term alimentary mucositis encompasses both oral and GI mucositis. Mucositis can be classified according to the type of cancer therapy involved as chemotherapy-induced mucositis, radiation-induced mucositis, or a combination of the two. More recently, mucositis following targeted anticancer therapies has been described, but our understanding of that is only beginning to develop. Mucositis can be very painful and can significantly affect nutritional intake, mouth care, and quality of life. It can sometimes be a dose-limiting toxicity of cancer therapy and thus have direct effects on patient survival. This chapter presents a comprehensive discussion on mucositis including its morbidity, economic impact, pathogenesis, risk factors, clinical signs and symptoms, diagnosis and complicating factors, and measurement. In addition, preventive measures, pain control, nutritional support, and therapeutic interventions (including therapies in development) for mucositis are discussed, with reference to the MASCC/ISOO clinical practice guidelines, where applicable.


Oral Mucositis Hematopoietic Cell Transplantation Severe Mucositis Patient Receive Radiation Therapy Mouth Care 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Jones JA, Avritscher EB, Cooksley CD, Michelet M, Bekele BN, Elting LS. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer. 2006;14(6):505–15.PubMedCrossRefGoogle Scholar
  2. 2.
    Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66(3):253–62.PubMedCrossRefGoogle Scholar
  3. 3.
    McGuire DB, Altomonte V, Peterson DE, Wingard JR, Jones RJ, Grochow LB. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nurs Forum. 1993;20(10):1493–502.PubMedGoogle Scholar
  4. 4.
    Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003;98(7):1531–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Duncan GG, Epstein JB, Tu D, El Sayed S, Bezjak A, Ottaway J, et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head Neck. 2005;27(5):421–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ. Patient reports of complications of bone marrow transplantation. Support Care Cancer. 2000;8(1):33–9.PubMedGoogle Scholar
  7. 7.
    Rapoport AP, Miller Watelet LF, Linder T, Eberly S, Raubertas RF, Lipp J, et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol. 1999;17(8):2446–53.PubMedGoogle Scholar
  8. 8.
    Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer. 1998;82(11):2275–81.PubMedCrossRefGoogle Scholar
  9. 9.
    Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007;68:1110–20.PubMedCrossRefGoogle Scholar
  10. 10.
    Bowen JM, Keefe DM. New pathways for alimentary mucositis. J Oncol. 2008;2008:907892.PubMedCrossRefGoogle Scholar
  11. 11.
    Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100(9 Suppl):1995–2025.PubMedCrossRefGoogle Scholar
  12. 12.
    Sonis ST, Peterson RL, Edwards LJ, Lucey CA, Wang L, Mason L, et al. Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol. 2000;36(4):373–81.PubMedCrossRefGoogle Scholar
  13. 13.
    Dorr W, Emmendorfer H, Haide E, Kummermehr J. Proliferation equivalent of ‘accelerated repopulation’ in mouse oral mucosa. Int J Radiat Biol. 1994;66(2):157–67.PubMedCrossRefGoogle Scholar
  14. 14.
    Bowen JM, Gibson RJ, Tsykin A, Stringer AM, Logan RM, Keefe DM. Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy. Int J Cancer. 2007;121:1847–56.PubMedCrossRefGoogle Scholar
  15. 15.
    Sonis S, Haddad R, Posner M, Watkins B, Fey E, Morgan TV, et al. Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol. 2007;43(3):289–300.PubMedCrossRefGoogle Scholar
  16. 16.
    Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol. 2004;22(7):1268–75.PubMedCrossRefGoogle Scholar
  17. 17.
    Bogunia-Kubik K, Polak M, Lange A. TNF polymorphisms are associated with toxic but not with aGVHD complications in the recipients of allogeneic sibling haematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;32(6):617–22.PubMedCrossRefGoogle Scholar
  18. 18.
    Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol. 2003;39(2):91–100.PubMedCrossRefGoogle Scholar
  19. 19.
    National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE); 2006. Available from:
  20. 20.
    Sonis ST, Eilers JP, Epstein JB, LeVeque FG, Liggett WH, Jr., Mulagha MT, et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer. 1999;85(10):2103–13.PubMedCrossRefGoogle Scholar
  21. 21.
    Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109(5):820–31.PubMedCrossRefGoogle Scholar
  22. 22.
    Cheng KK, Molassiotis A, Chang AM, Wai WC, Cheung SS. Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients. Eur J Cancer. 2001;37(16):2056–63.PubMedCrossRefGoogle Scholar
  23. 23.
    Levy-Polack MP, Sebelli P, Polack NL. Incidence of oral complications and application of a preventive protocol in children with acute leukemia. Spec Care Dentist. 1998;18(5):189–93.PubMedCrossRefGoogle Scholar
  24. 24.
    Borowski B, Benhamou E, Pico JL, Laplanche A, Margainaud JP, Hayat M. Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomised controlled trial comparing two protocols of dental care. Eur J Cancer B Oral Oncol. 1994;30B(2):93–7.PubMedCrossRefGoogle Scholar
  25. 25.
    McGuire DB, Correa ME, Johnson J, Wienandts P. The role of basic oral care and good clinical practice principles in the management of oral mucositis. Support Care Cancer. 2006;14(6):541–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Migliorati CA, Oberle-Edwards L, Schubert M. The role of alternative and natural agents, cryotherapy, and/or laser for management of alimentary mucositis. Support Care Cancer. 2006;14(6):533–40.PubMedCrossRefGoogle Scholar
  27. 27.
    Barasch A, Elad S, Altman A, Damato K, Epstein J. Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis. Support Care Cancer. 2006;14(6):528–32.PubMedCrossRefGoogle Scholar
  28. 28.
    Cheng KK. Oral mucositis, dysfunction, and distress in patients undergoing cancer therapy. J Clin Nurs. 2007;16:2114–21.PubMedCrossRefGoogle Scholar
  29. 29.
    Raber-Durlacher J, Barasch A, Peterson DE, Lalla RV, Schubert MM, Fibbe WE. Oral complications and management considerations in patients treated with high-dose cancer chemotherapy. Supportive Cancer Ther. 2004;1(4):219–29.CrossRefGoogle Scholar
  30. 30.
    Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351(25):2590–8.PubMedCrossRefGoogle Scholar
  31. 31.
    von Bultzingslowen I, Brennan MT, Spijkervet FK, Logan R, Stringer A, Raber-Durlacher JE, et al. Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal ­mucositis. Support Care Cancer. 2006;14(6):519–27.CrossRefGoogle Scholar
  32. 32.
    Lopes NN, Plapler H, Chavantes MC, Lalla RV, Yoshimura EM, Alves MT. Cyclooxygenase-2 and vascular endothelial growth ­factor expression in 5-fluorouracil-induced oral mucositis in hams­ters: evaluation of two low-intensity laser protocols. Support Care Cancer. 2009;17:1409–15.PubMedCrossRefGoogle Scholar
  33. 33.
    Peterson DE, Jones JB, Petit RG, II. Randomized, placebo-­controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer. 2007;109(2):322–31.PubMedCrossRefGoogle Scholar
  34. 34.
    Papas AS, Clark RE, Martuscelli G, O’Loughlin KT, Johansen E, Miller KB. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;31(8):705–12.PubMedCrossRefGoogle Scholar
  35. 35.
    Epstein JB, Silverman S, Jr., Paggiarino DA, Crockett S, Schubert MM, Senzer NN, et al. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo- controlled clinical trial. Cancer. 2001;92(4):875–85.PubMedCrossRefGoogle Scholar
  36. 36.
    Lalla RV, Schubert MM, Bensadoun RJ, Keefe D. Anti-inflammatory agents in the management of alimentary mucositis. Support Care Cancer. 2006;14(6):558–65.PubMedCrossRefGoogle Scholar
  37. 37.
    Bensadoun RJ, Schubert MM, Lalla RV, Keefe D. Amifostine in the management of radiation-induced and chemo-induced mucositis. Support Care Cancer. 2006;14(6):566–72.PubMedCrossRefGoogle Scholar
  38. 38.
    Al-Dasooqi N, Gibson R, Bowen J, Keefe D. HER2 targeted therapies for cancer and the gastrointestinal tract. Curr Drug Targets. 2009;10(6):537–42.PubMedCrossRefGoogle Scholar
  39. 39.
    Sonis ST. A biological approach to mucositis. J Support Oncol. 2004;2:21–36.PubMedGoogle Scholar
  40. 40.
    Lalla RV, et al. Management of oral mucositis in patients who have cancer. Dent Clin North Am. 2008;52(1):61–77, viii.PubMedCrossRefGoogle Scholar
  41. 41.
    World Health Organization. Handbook for reporting results of ­cancer treatment. Geneva: World Health Organization; 1979:15–22.Google Scholar

Copyright information

© Society for Imaging Informatics in Medicine 2010

Authors and Affiliations

  1. 1.Section of Oral MedicineUniversity of Connecticut Health CenterFarmingtonUSA

Personalised recommendations